stack of letters mail envelopes
Biotech

FDA details Regenxbio rare disease rejection

The agency's rationale should have little impact on Denali Therapeutics, which is awaiting a decision on its own Hunter syndrome candidate.
Darren Incorvaia Mar 3, 2026 12:56pm
cash money

Biotech's top money raisers: 2025

Mar 2, 2026 6:30am
How physiology powers biotech innovation

How physiology powers biotech innovation

Brought to you by American Physiological Society
warning sign

New cancer cases prompt Kyowa to shutter rocatinlimab trials

Mar 3, 2026 11:00am
closed close

Theravance halves headcount, ends R&D work after ph. 3 fail

Mar 3, 2026 12:08pm
big wave over ship in storm

Disc lays off 20% of workforce in wake of FDA rejection

Mar 3, 2026 10:45am
More News

Biohaven reduces scope of R&D cuts as pipeline progresses

Mar 3, 2026 9:00am

How GLP-1s help the heart relax: study

Mar 2, 2026 7:01pm

HHS bans Anthropic's Claude AI tool

Mar 2, 2026 5:17pm

Boehringer axes MASH deal after OSE asset fails to show efficacy

Mar 2, 2026 2:16pm